COZADD BRUCE C 4

What Happened Bruce C. Cozadd, a director of Jazz Pharmaceuticals plc (JAZZ), sold 6,000 shares in an open-market transaction on June 1, 2026 at $235.12 per share, generating proceeds of $1,410,720. This was a sale (not a purchase) and therefore is typically viewed as routine insider liquidity rather than a direct bullish signal.

Key Details

• Transaction date and price: 2026-06-01, 6,000 shares at $235.12 each.
• Total proceeds: $1,410,720.
• Filing date: Form 4 filed 2026-06-03 (timely — within the standard two business days).
• Footnote: The sale was made under a Rule 10b5-1 trading plan adopted by Mr. Cozadd on November 26, 2025; the transaction occurred automatically and was non‑discretionary (per footnote F1).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Transaction code: S = Sale.

Context A 10b5-1 plan lets insiders sell according to pre-set instructions, which reduces the likelihood the sale reflects new private information or the insider’s current view of the company. For retail investors, routine 10b5-1 sales are common; purchases (insider buys) generally carry more weight when interpreting insider sentiment.